Literature DB >> 27402380

Response to Letter to the Editor on "Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?".

Claudio A Bravo1, Dorothy E Vatner1, Stephen F Vatner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27402380      PMCID： PMC6047221          DOI： 10.1124/jpet.116.234807

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  15 in total

1.  Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress.

Authors:  Satoshi Okumura; Dorothy E Vatner; Reiko Kurotani; Yunzhe Bai; Shumin Gao; Zengrong Yuan; Kousaku Iwatsubo; Coskun Ulucan; Jun-ichi Kawabe; Kaushik Ghosh; Stephen F Vatner; Yoshihiro Ishikawa
Journal:  Circulation       Date:  2007-09-24       Impact factor: 29.690

2.  Type 5 adenylyl cyclase disruption increases longevity and protects against stress.

Authors:  Lin Yan; Dorothy E Vatner; J Patrick O'Connor; Andreas Ivessa; Hui Ge; Wei Chen; Shinichi Hirotani; Yoshihiro Ishikawa; Junichi Sadoshima; Stephen F Vatner
Journal:  Cell       Date:  2007-07-27       Impact factor: 41.582

3.  Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling.

Authors:  Tong Tang; Mei Hua Gao; N Chin Lai; Amy L Firth; Toshiyuki Takahashi; Tracy Guo; Jason X-J Yuan; David M Roth; H Kirk Hammond
Journal:  Circulation       Date:  2007-12-10       Impact factor: 29.690

4.  Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase.

Authors:  Kosaku Iwatsubo; Claudio Bravo; Masami Uechi; Erdene Baljinnyam; Takashi Nakamura; Masanari Umemura; Lo Lai; Shumin Gao; Lin Yan; Xin Zhao; Misun Park; Hongyu Qiu; Satoshi Okumura; Mizuka Iwatsubo; Dorothy E Vatner; Stephen F Vatner; Yoshihiro Ishikawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-13       Impact factor: 4.733

5.  Activated expression of cardiac adenylyl cyclase 6 reduces dilation and dysfunction of the pressure-overloaded heart.

Authors:  Yasuo Sugano; N Chin Lai; Mei Hua Gao; Amy L Firth; Jason X-J Yuan; Wilbur Y W Lew; H Kirk Hammond
Journal:  Biochem Biophys Res Commun       Date:  2010-12-30       Impact factor: 3.575

6.  Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation.

Authors:  Tong Tang; N Chin Lai; Adam T Wright; Mei Hua Gao; Paul Lee; Tracy Guo; Ruoying Tang; Andrew D McCulloch; H Kirk Hammond
Journal:  J Mol Cell Cardiol       Date:  2013-04-12       Impact factor: 5.000

7.  Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure.

Authors:  N Chin Lai; David M Roth; Mei Hua Gao; Tong Tang; Nancy Dalton; Yin Yin Lai; Matthew Spellman; Paul Clopton; H Kirk Hammond
Journal:  Circulation       Date:  2004-07-12       Impact factor: 29.690

8.  Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice.

Authors:  N Chin Lai; Tong Tang; Mei Hua Gao; Miho Saito; Toshiyuki Takahashi; David M Roth; H Kirk Hammond
Journal:  J Am Coll Cardiol       Date:  2008-04-15       Impact factor: 24.094

9.  A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion.

Authors:  Claudio A Bravo; Dorothy E Vatner; Ronald Pachon; Jie Zhang; Stephen F Vatner
Journal:  J Pharmacol Exp Ther       Date:  2016-03-03       Impact factor: 4.030

10.  Adenylyl Cyclase Type 5 Deficiency Protects Against Diet-Induced Obesity and Insulin Resistance.

Authors:  David Ho; Xin Zhao; Lin Yan; Chujun Yuan; Haihong Zong; Dorothy E Vatner; Jeffery E Pessin; Stephen F Vatner
Journal:  Diabetes       Date:  2015-03-02       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.